News

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies Ghent, Belgium, 6th January 2026 – Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has entered into an agreement with Ardena to manufacture their lead […]

Ghent, Belgium – November 3, 2025 — Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointment of Dipesh Patel as Chief Quality Officer and Peter Rose as Chief Information Officer. These appointments strengthen Ardena’s executive leadership team and reflect its continued focus on quality, compliance, and […]

Peptinovo Biopharma Selects Ardena as Manufacturing Partner to Advance Its Novel Cancer Nanotechnology Toward Clinical Trials Ghent, Belgium, 16th October 2025 – Peptinovo Biopharma, a biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today announced a strategic manufacturing partnership with Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO) and bioanalytical […]

Ghent, Belgium, 21st August 2025 Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced a strategic partnership with MAXONA Pharmaceuticals, a clinical-stage pharmaceutical company committed to developing the next generation of therapies to help patients maximize life. The collaboration will support the development and manufacturing of MAX-001, […]

Ghent, Belgium, 13th June 2025 A suite of nanoparticle-based immunotherapies developed by Topas Therapeutics has successfully progressed into clinical trials, supported end-to-end regarding Chemistry, Manufacturing, and Control (CMC) by Ardena, a specialist partner in the development and manufacturing of complex formulations and precision medicines. Topas Therapeutics, based in Hamburg, Germany, is pioneering a highly differentiated […]

Ghent, Belgium, 28th May 2025 Ardena, a specialist service provider in integrated drug development, today announced a new milestone at its newly established bioanalytical laboratory at Pivot Park in Oss, Netherlands. Following successful commissioning of the facility earlier this year, the site has already initiated several client projects and completed its first sample testing earlier […]

Ghent, Belgium, 4th February 2025 Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) with facilities in Belgium, Spain, the Netherlands, and Sweden, today announced that it has successfully completed the acquisition of Catalent’s state-of-the-art drug product manufacturing facility in Somerset, New Jersey. This acquisition marks a significant […]

Oss, The Netherlands — Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) with GMP facilities in Belgium, Spain, the Netherlands, and Sweden, announces the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss. Granted by the Dutch Healthcare Authority, the approval enables GMP manufacturing operations for nanomedicines, marking a […]

Ghent, Belgium, 29th October 2024 Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced a substantial expansion of its Bioanalytical Services in the Netherlands. This strategic investment includes establishing a brand new bioanalytical lab at Ardena’s Pivot Park facility in Oss, along […]

Ghent, Belgium, 14th October 2024 Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey. This acquisition will significantly enhance Ardena’s capabilities in downstream late-stage and small-scale commercial […]

July 16, 2024 Ghent, Belgium – Ardena (the “Company”) announces several key promotions to its executive leadership team, reflecting the Company’s commitment to driving growth and international expansion and fostering diversity and talent development. Ariane De Ganck promoted to Division Head, Drug Product Services Ariane De Ganck, based in Ghent, Belgium, has been promoted to […]

June 3rd, 2024 Ghent, Belgium – Ardena (the “Company”) today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive Officer. Jeremie is a seasoned executive in the pharmaceutical Contract Development and Manufacturing Operations (CDMO) industry. Harry will step down as CEO after 20 years of leading the […]